Recent Press Releases

ACTELION DELIVERS EXCELLENT FIRST HALF 2015 RESULTS

ACTELION DELIVERS EXCELLENT FIRST HALF 2015 RESULTS ALLSCHWIL/BASEL, SWITZERLAND - 21 July 2015 - Actelion Ltd (SIX: ATLN) today announced its results for the first six months of 2015. OPERATING...

NeuroCog Trials Names Leading Industry Professional To Head Business Development

NeuroCog Trials Names Leading Industry Professional To Head Business Development DURHAM, N.C., July 20, 2015 /PRNewswire/ -- NeuroCog Trials announced the appointment of Brian K. Saxby, PhD, to the...

Abbott's iDesign System Creates 3-D Map of the Eye for Precise, Personalized LASIK Vision Treatment

- FDA approves iDesign Advanced WaveScan Studio System for use in LASIK procedures in the U.S.

ABBOTT PARK, Ill., July 20, 2015 /PRNe

CASI Pharmaceuticals Announces Availabilty Of Anti-Cancer Drug ZEVALIN® In Hong Kong For Non-Hodgkin's Lymphoma

CASI Pharmaceuticals Announces Availabilty Of Anti-Cancer Drug ZEVALIN® In Hong Kong For Non-Hodgkin's Lymphoma ROCKVILLE, Md., July 20, 2015 /PRNewswire/ -- CASI Pharmaceuticals, Inc....

CheckMate -025, a Pivotal Phase III Opdivo (nivolumab) Renal Cell Cancer Trial, Stopped Early

Opdivo Demonstrates Superior Overall Survival Compared to Everolimus in Patients with Previously-Treated Advanced or Metastatic Renal Cell Carcinoma (PRINCETON, NJ, July 20, 2015) –...

Roche expands HIV Global Access Program to include infants in resource limited settings

Program adds early infant testing to further support the 90:90:90 UNAIDS goal

EISAI ENTERS AGREEMENT TO TRANSFER NORTH CAROLINA PLANT IN THE U.S. TO BIOGEN

EISAI ENTERS AGREEMENT TO TRANSFER NORTH CAROLINA PLANT IN THE U.S. TO BIOGEN July 16, 2015 - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.S....

Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

THOUSAND OAKS, Calif., July 16, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the top-line results of a Phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and...

Valeant Pharmaceuticals Agrees To Acquire Amoun Pharmaceutical

LAVAL, Quebec , July 17, 2015 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has entered into a definitive agreement under which Valeant will...

Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

THOUSAND OAKS, Calif., July 16, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the top-line results of a Phase 2 o

GSK begins shipping 2015-16 US flu vaccines with focus on customer needs, volume, and speed

- Supply shifts to 100% four-strain vaccines

PHILADELPHIA, July 16, 2015 /PRNewswire/ -- GSK (L

GSK Press Release: GSK begins shipping 2015-16 US flu vaccines with focus on customer needs, volume, and speed

Supply shifts to 100% four-strain vaccines - 32-38 million doses expected, an increase over last year GSK [LSE/NYSE: GSK] announced today it has begun shipping FLUARIX® QUADRIVALENT (Influenza...

NEJM: Analysis of Delamanid (Deltyba™) Data Shows Positive Efficacy Results for Treatment of XDR-TB

Analysis of data from Phase IIb trial showed that delamanid plus a background regimen may be a promising treatment option in complex, difficult-to-treat XDR-TB patients.i · Delamanid...

Novartis malaria treatment Coartem(R) 80/480mg receives WHO prequalification, enabling greater access for patients

WHO prequalified Coartem® 80/480mg is the first and only high strength malaria treatment available for donor-funded public sector procurement Coartem® 80/480mg reduces the pill burden for...

Award-Winning Actress S. Epatha Merkerson, Merck and the American Diabetes Association Challenge African Americans with Type 2 Diabetes to Get to Their A1C Goal

Merkerson Visits Raleigh on July 15 as Part of America's Diabetes Challenge: Get to Your Goals Program

KENILWORTH, N.J.,

SANOFI ANNOUNCES NEW, GLOBAL BUSINESS UNIT STRUCTURE TO DRIVE FUTURE GROWTH

Deepens specialization and allows clear focus on growth drivers Three, new Global Business Units for General Medicines & Emerging Markets, Specialty Care, and Diabetes & Cardiovascular...

Ardelyx to Provide Updates on Research and Development Programs at Today's Inaugural R&D Day in New York City

Tenapanor development plans will be presented along with new data demonstrating sustained response in IBS-C

FREMONT, Calif.,

Bayer receives European approval for Gadovist® (gadobutrol) for use in pediatric patients less than 2 years of age

Leverkusen, July 14, 2015 – Bayer HealthCare announced today that Gadovist® (gadobutrol) has received a label extension in the European Union (EU) for diagnostic use with magnetic resonance...

Consumer and Public Interest Groups Write To FTC Opposing Teva's Hostile Takeover of Mylan

Washington, D.C. – Today, consumer advocacy groups including Consumers Union, Consumer Federation of America, US PIRG, Consumer Action, Consumer Watchdog, Public Citizen, and National Center...